Neutral boron [(L1-3)BPh2] and cationic charged boron [(L1a-3a)BPh2] complexes for chemical CO₂ conversion to obtain cyclic carbonates under ambient conditions

Abstract

Three neutral salen ligands (L1-3) with three cationic charged salen ligands (L1a-3a) and the corresponding neutral boron [(L1-3)BPh2] and cationic charged boron [(L1a-3a)BPh2] compounds have been successfully synthesized and characterized under ambient conditions.

Conversion of CO2 into Chloropropene Carbonate Catalyzed by Iron (II) Phthalocyanine Hypercrosslinked Porous Organic Polymer

“…The optimal reaction conditions were established using epichlorohydrin (ECH) as substrate and dimethylamino pyridine DMAP as base. Epiclorohydrin was selected as model substrate because is one of the most interesting epoxides that can be produced from glycerin obtained from vegetable oil [ 32 ] and DMAP as base due its proved efficiency compared with other bases [ 12 , 33 , 34 , 35 ]. The excellent catalytic activity in presence of this base was firstly reported by Paddok et al [ 36 ] who attributed it to the coordination of DMAP to the metal generating more electron-rich centers in the metal-catalyst.…”

A Novel Dopamine‐Based Boronate Esters with the Organic Base as Highly Efficient, Stable, and Green Catalysts for the Conversion of CO2 with Epoxides to Cyclic Carbonates

“…The epichlorohydrin showed the highest activity due to the electron‐withdrawing effect of its substituent, which facilitated nucleophilic attack to open the epoxide ring. [ 17,51,52 ] The VCHO and CHO showed the lowest activity, which might be presumably due to the high steric hindrance caused by its ring structure. A similar effect was observed in our previous studies.…”

Synthesis of cis‐1,2‐diol‐type chiral ligands and their dioxaborinane derivatives: Application for the asymmetric transfer hydrogenation of various ketones and biological evaluation

“…Other characteristic bands appeared at approximately 1,660 cm −1 correspond to the stretching vibrations of imine υ(C=N) group of chiral ligands (T 1 and T 2 ), whereas the imine υ(C=N) stretching vibrations of complexes (T (1-2) B (1-2) ) and (T (1-2) B (1-2) -N) appeared in the range of 1,649-1,643 and 1,646-1,636 cm −1 , respectively. [16,[43][44][45] Moreover, the two new characteristic peaks in the range of 1,274-1,261 and 820-817 cm −1 correspond to the stretching vibrations of υ(B-O) and υ(B-C) groups of chiral dioxaborinane derivatives (T (1-2) B (1-2) ) and (T (1-2) B (1-2) -N), respectively. [26,46] Furthermore, two peaks observed in the range of 1,382-1,365 and 486-480 cm −1 , which could be attributed to ferrocene υ(C-C) and υ (Fe-C) stretchings in the framework of chiral dioxaborinane complexes, respectively.Electronic transitions of ligands (T 1 and T 2 ) and their chiral dioxaborinane (T (1-2) B (1-2) ) and (T (1-2) B (1-2) -N) complexes were studied in C 2 H 5 OH and CHCl 3 (2.10 −6 -2.10 −8 M) at room temperature and recorded at λ max as nm.…”

“…[6][7][8] Because of the aforementioned reasons, starting from relatively simple reagents, dioxaborinane complexes containing an N ! B dative bond have successfully been developed including fluorescence, [9] electrochemical, [10] enzymebased sensing, [11] pharmaceutical applications, [12,13] catalytic applications, [14][15][16][17] antioxidant and antimicrobial applications [18][19][20][21][22][23][24] etc.…”

“…For this purpose, in recent years, significant advances for developing a wide range of effective catalytic systems and improvement studies toward enhancing the selectivity and practicability of the main group of catalysts, especially boron catalysts, have been accomplished. [14][15][16][17] Besides, main-group elements (p-block elements) offer great potential since they allow the activation of various chemical bonds and, consequently enable chemical transformations. [29,30] In addition, boron-containing compounds have been explored as inhibitors for different biological targets and some of them were approved by FDA as the drugs to treat a variety of diseases such as multiple myeloma, cancer, etc.…”